Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ipratropium bromide.

K L Massey, V P Gotz

    Drug Intelligence & Clinical Pharmacy
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Anticholinergic therapy with ipratropium bromide offers a new option for managing chronic obstructive pulmonary disease (COPD). It provides bronchodilation and is well-tolerated, especially in combination therapies for chronic bronchitis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The laboratory approach to thyroid disease.

    Canadian family physician Medecin de famille canadien·2011
    Same author

    What can YOU do about health care costs?

    Canadian Medical Association journal·2010
    Same author

    Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.

    Clinical transplantation·2005
    Same author

    Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.

    Transplantation proceedings·2005
    Same author

    Knowledge-based test result in interpretation in laboratory medicine.

    Clinica chimica acta; international journal of clinical chemistry·1999
    Same author

    Acebutolol overdose treated with hemodialysis and extracorporeal membrane oxygenation.

    Journal of clinical pharmacology·1996
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Area of Science:

    • Pulmonary Medicine
    • Pharmacology

    Background:

    • Research into the parasympathetic nervous system's role in chronic obstructive pulmonary disease (COPD) pathophysiology has spurred interest in anticholinergic therapies.
    • Ipratropium bromide, an investigational agent, acts as a bronchodilator by competitively inhibiting cholinergic receptors on bronchial smooth muscle.

    Purpose of the Study:

    • To evaluate the efficacy and safety of ipratropium bromide in managing COPD, particularly chronic bronchitis.
    • To explore its potential role as an alternative or adjunctive therapy.

    Main Methods:

    • Administration of ipratropium bromide via inhalation at therapeutic doses (20-40 micrograms).
    • Comparison of ipratropium bromide's effectiveness against beta-agonists and sympathomimetics.
    • Assessment of combination therapy with beta-agonists or theophylline.

    Related Experiment Videos

    Main Results:

    • Ipratropium bromide is less effective than beta-agonists in asthmatics but comparable or superior to sympathomimetics in chronic bronchitis.
    • Combination therapy with beta-agonists or theophylline demonstrated enhanced effects.
    • The drug was well-tolerated with minimal adverse reactions due to low serum concentrations.

    Conclusions:

    • Ipratropium bromide presents a viable alternative to beta-agonists for COPD patients with poor response or side effects.
    • Combination therapy represents a significant potential use for ipratropium in COPD management.